- Analysis
- Barani Krishnan
- 3
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, and essential liquids; mouthwash; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits; paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab for the treatment of non-small cell lung cancer; and anti-PD1 for advanced cancers. The company was founded in 2000 and is based in Hefei, China.
Metrics to compare | 300009 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300009PeersSector | |
---|---|---|---|---|
P/E Ratio | 18.2x | 22.4x | −0.6x | |
PEG Ratio | 9.84 | 0.20 | 0.00 | |
Price/Book | 3.6x | 2.0x | 2.6x | |
Price / LTM Sales | 5.2x | 6.7x | 3.1x | |
Upside (Analyst Target) | 25.6% | 32.8% | 52.8% | |
Fair Value Upside | Unlock | 22.3% | 8.4% | Unlock |